| Autor: |
Shworak, Nicholas, HajMohammadi, Sassan, de Agostini, Ariane, Rosenberg, Robert |
| Zdroj: |
Glycoconjugate Journal; May2002, Vol. 19 Issue 4/5, p355-361, 7p |
| Abstrakt: |
Heparan sulfate that contains antithrombin binding sites is designated as anticoagulant heparan sulfate (HSact) since, in vitro, it dramatically enhances the neutralization of coagulation proteases by antithrombin. Endothelial cell production of HSact is controlled by the Hs3st1 gene, which encodes the rate limiting enzyme—heparan sulfate 3- O-sulfotransferase-1 (Hs3st1). It has long been proposed that levels of endothelial HSact may tightly regulate hemostatic tone. This potential in vivo role of HSact was assessed by generating Hs3st1−/− knockout mice. Hs3st1−/− and Hs3st1+/+ mice were evaluated with a variety of methods, capable of detecting altered hemostatic tone. However, both genotypes were indistinguishable. Instead, Hs3st1−/− mice exhibited lethality on a specific genetic background and also showed intrauterine growth retardation. Neither phenotypes result from a gross coagulopathy. So although this enzyme produces the majority of tissue HSact, Hs3st1−/− mice do not show an obvious procoagulant phenotype. These results suggest that the bulk of HSact is not essential for normal hemostasis and that hemostatic tone is not tightly regulated by total levels of HSact. Moreover, the unanticipated non-thrombotic phenotypes suggest structure(s) derived from this enzyme might serve additional/alternative biologic roles. Published in 2003. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink